Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.

IF 2.2 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-03-01 Epub Date: 2026-01-12 DOI:10.1080/14737167.2026.2615680

Sonia Santos-Lasaosa, Beatriz Armada, Carlota Moya-Alarcón, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo Irimia

{"title":"Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.","authors":"Sonia Santos-Lasaosa, Beatriz Armada, Carlota Moya-Alarcón, Darío Rubio-Rodríguez, Carlos Rubio-Terrés, Pablo Irimia","doi":"10.1080/14737167.2026.2615680","DOIUrl":null,"url":null,"abstract":"Objective: To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain.Methods: A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, from the perspective of the Spanish National Health System (SNHS). The cost per patient of all AEs described with RIM or LAS in 12 clinical trials, obtained through a systematic review, was analyzed. Several sensitivity analyzes (among them, a matching adjusted indirect comparison -MAIC- of the two long-term studies) were also performed. The cost of AEs management (€ 2024) was obtained from Spanish sources.Results: The probabilistic model estimated that RIM compared to LAS would generate savings of €612.79 (95% CI €159.49-1339.43) per treated patient with migraine, in a treatment period of 6.11 ± 3.25 months, €98.54 per month. In the MAIC analysis, a saving per patient of €697.04 (95% CI: €514.44-879.04) was obtained in a treatment period of 12.4 months. The probability of RIM saving in all analysis was 100%.Conclusions: In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"361-368"},"PeriodicalIF":2.2000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2026.2615680","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To compare the cost of adverse events (AEs) associated with the acute treatment with rimegepant (RIM) versus lasmiditan (LAS) for migraine in Spain.

Methods: A probabilistic modeling analysis was performed, using second-order Monte Carlo simulations, from the perspective of the Spanish National Health System (SNHS). The cost per patient of all AEs described with RIM or LAS in 12 clinical trials, obtained through a systematic review, was analyzed. Several sensitivity analyzes (among them, a matching adjusted indirect comparison -MAIC- of the two long-term studies) were also performed. The cost of AEs management (€ 2024) was obtained from Spanish sources.

Results: The probabilistic model estimated that RIM compared to LAS would generate savings of €612.79 (95% CI €159.49-1339.43) per treated patient with migraine, in a treatment period of 6.11 ± 3.25 months, €98.54 per month. In the MAIC analysis, a saving per patient of €697.04 (95% CI: €514.44-879.04) was obtained in a treatment period of 12.4 months. The probability of RIM saving in all analysis was 100%.

Conclusions: In accordance with this model, the favorable safety profile of RIM compared to LAS would generate savings for the SNHS in health-care resources in all the scenarios considered.

查看原文本刊更多论文

西班牙偏头痛急性治疗中瑞米坦和拉西米坦相关不良事件的成本。

目的：比较西班牙偏头痛患者急性治疗时使用利美吉坦（RIM）和拉斯米坦（LAS）的不良事件（ae）成本。方法：从西班牙国家卫生系统（SNHS）的角度出发，采用二阶蒙特卡罗模拟进行概率建模分析。通过系统评价，分析了12项临床试验中所有用RIM或LAS描述的ae的每位患者的成本。还进行了几项敏感性分析（其中，两项长期研究的匹配调整间接比较- maic）。AEs管理费用（2024欧元）来自西班牙。结果：概率模型估计，在6.11±3.25个月的治疗期间，与LAS相比，RIM将为每位治疗的偏头痛患者节省612.79欧元（95% CI€159.49-1339.43），每月98.54欧元。在MAIC分析中，在12.4个月的治疗期间，每位患者节省了697.04欧元（95% CI: 514.44-879.04欧元）。在所有分析中，RIM节省的概率为100%。结论：根据该模型，在所有考虑的情况下，与LAS相比，RIM的良好安全性将为SNHS节省医疗资源。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.